Skip to content

Immuno-oncology

Immuno-oncology

Multi-omics profiling of tumors and their microenvironment, for biomarkers of response, resistance and stratification.

6
analyses
4
questions
1
program

Programs

Our programs

Xplorer™ program

Biomarker Xplorer™

Find the markers that separate two groups, and confirm them before you build on them.

  • DNA, RNA and proteins read against one question
  • Bulk RNA-seq; single-cell and spatial through Transcriptomics 360
  • Confirmation by qPCR or dPCR on the full sample set
3
levels: DNA, RNA, proteins
4
questions
9
application areas

Questions

The questions we take on

A designed program rather than an analysis order: GENXMAP integrates genomic, transcriptomic, proteomic and tumor-microenvironment data to identify molecular signatures associated with treatment response or resistance and, where an independent cohort is available, tests those signatures in data they were not derived from.

Question 1

Response

Which patients respond to checkpoint blockade, and what separates them molecularly

  • Genomic profilingWGS · WES
  • Bulk RNA sequencingtumor tissue
  • ProteomicsTIMS-TOF MS

Question 2

Microenvironment

How the immune composition of the microenvironment shifts under treatment

  • Tumor microenvironmentimmune deconvolution
  • Single-cell and spatialthrough Transcriptomics 360

Question 3

Validation

Whether a candidate signature holds on an independent cohort

  • Multi-cohort integrationbatch correction
  • Targeted mutation validationtargeted sequencing
  • Signature discoveryindependent cohorts

Question 4

Outcome

How molecular findings line up with treatment arm and clinical outcome

  • Liquid biopsycfDNA · cfRNA
  • Signatures and modelsarm · outcome
Three modalities, one program

One transcriptome, three resolutions

In immuno-oncology, knowing that the global expression changed is rarely enough. You need to know which immune subsets moved, and where they sit relative to the tumor. That is three modalities, not one: bulk RNA-seq on our own platforms, single-cell and spatial transcriptomics through Transcriptomics 360. Run as one program, on one design and one sample set, they are read together rather than reconciled afterwards.

Networks and cohorts

GENXMAP is a member of the Paris-Saclay Cancer Cluster and the Marseille Immunology Biocluster. For a program that needs a specific cohort or a clinical collaborator, that is the difference between a conversation and a search.

See the Transcriptomics 360 offering

Your study

How a study runs

  1. 01

    Question and design

    The work starts before the analysis: defining which molecular layers are needed to answer the biological question, selecting appropriate references, determining how cohorts will be integrated, and separating discovery from validation from the outset.

  2. 02

    Samples

    FFPE blocks and slides, fresh-frozen tumor tissue, core biopsies, PBMC, whole blood, plasma and dissociated cell suspensions.

  3. 03

    Laboratory measurement

    Tumor and immune compartments are extracted and quality-controlled in our Marseille laboratories, then measured on our platforms (single-cell and spatial transcriptomics through Transcriptomics 360), and returned as primary data your team can analyze directly or hand to GENXMAP.

  4. 04

    Interpretation

    Interpretation written against the question the study started from, stating what the data support and what they do not.

  5. 05

    Deliverables

    A QC report for every sample, then the data package for audit or reproduction by a third party.

What the analysis covers

Six layers, read against the same question

Genomic profiling
Somatic calling from WGS or WES, with burden, mutational signatures and copy number summarized per sample and per arm. Selected variants confirmed by targeted sequencing or dPCR.
Transcriptomic and immune profiling
Differential expression at gene and pathway level, immune program scores, and cell-type composition from bulk RNA-seq, cross-checked against single-cell references where available. Single-cell and spatial annotation where the Transcriptomics 360 program is run.
Proteomic profiling
Label-free LC-MS/MS performed on site on a timsTOF Pro 2, and differential abundance, matched against the transcriptomic result.
Liquid-biopsy monitoring
cfDNA and cfRNA signals per timepoint, set against tissue findings.
Cohort integration
Batch-corrected integration across cohorts and platforms, so a cohort accumulates instead of restarting.
Signatures and models
Responder and resistance signatures across layers, tested on independent data, and the models linking them to arm and outcome. Parameters, thresholds and versions recorded per study.

Working with what you have

The analysis does not have to start from our laboratory work. Genomic, transcriptomic, proteomic or liquid-biopsy data from an earlier study, an internal program or another provider can be analyzed on its own terms.

Integrating several layers

What determines the analysis is the biological question, the study design and the metadata available. Where several layers are available, we integrate them to find converging signals, separate robust effects from technical or cohort variability, and build the evidence around the biological question.

To scope a study, we need

  • 01The question
  • 02The cohort
  • 03The timeline

Laboratory work runs in our Marseille laboratories (extraction, QC, bulk RNA-seq), with single-cell and spatial transcriptomics through Transcriptomics 360 and proteomics on site; sample requirements, logistics and turnaround are defined per study.

What you receive

An integrated report

Laboratory
A QC report for every sample. Demultiplexed FASTQ with run-level QC metrics for the sequencing services. Result tables for PCR and protein work.
Report
Tool versions, parameters and thresholds for every step. QC metrics per sample and per cohort, with exclusions stated and justified. Interpretation written against the question the study started from, stating what the data support and what they do not.
Data package
Processed matrices, result tables, versioned pipelines and figures, delivered for audit or reproduction by a third party.

Practical terms

Report
PDF with a verifiable, time-stamped fingerprint
Data
Data is hosted in the EU, with backups in France, a separate space per team
Confidentiality
Mutual NDA available before any detail is shared, at no charge
AI
Models on our servers, no data sent to an external AI
Turnaround
In working days, confirmed in the quote, from GO

Sample requirements

Input amounts, RIN thresholds and DNA quality criteria are published per sample type. Archival and low-input material is handled routinely: if your material sits below the published thresholds, say so in the quote request and we will tell you what is feasible before you ship.

Where the bench stops

A platform order delivers primary data. Alignment, quantification, integration, biomarker discovery and modeling are run by our computational team within Biomarker Xplorer™: ask for it in the quote request and both are scoped together.

A project in this field?

Tell us the question, the cohort and the timeline.